OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press73710.17650/1818-8346-2009-0-2-28-34HEMATOLOGIC MALIGNANCIES: TREATMENT, SUPPORTIVE CAREГЕМОБЛАСТОЗЫ: ЛЕЧЕНИЕ, СОПРОВОДИТЕЛЬНАЯ ТЕРАПИЯDacogen administration experience for treatment of patients with myelodisplastic syndrome and chronic myelomonocytic leukemiaОпыт применения Дакогена для лечения больных миелодиспластическим синдромом и хроническим миеломоноцитарным лейкозомGritzaevS. V.ГрицаевС. В.
Russian Federation

St-Petersburg

Сергей Васильевич Грицаев

Санкт-Петербург

RNIIHT@mail.ruAbdulkadirovK. M.АбдулкадыровК. М.
Russian Federation

St-Petersburg

Санкт-Петербург

ShikhbabaevaD. I.ШихбабаеваД. И.
Russian Federation

St-Petersburg

Санкт-Петербург

MartinkevichI. S.МартынкевичИ. С.
Russian Federation

St-Petersburg

Санкт-Петербург

TiranovaS. A.ТирановаС. А.
Russian Federation

St-Petersburg

Санкт-Петербург

Russian Research Institute of Hematology and TransfusiologyФГУ Российский НИИ гематологии и трансфузиологии Федерального агентства по высокотехнологичной медицинской помощи270520092283425112022251120222009https://oncohematology.abvpress.ru/ongm/article/view/737

Dacogen treatment results of 8 MDS patients and 2 CMML patients (a course dose — 100 mg/m2) are presented. Hematological response according to modified IWG criteria (complete remission - 2 pts, bone marrow remission — 1 pts, disease stabilization — 4 pts) has been established in 70% of patients. Complete cytogenetic response has been achieved in one patient with secondary MDS and multiple chromosomal aberrations after 2 therapy courses. Complications because of which intercourse intervals elongated are registered in 3 patients. The obtained data demonstrated efficacy of Dacogen treatment for high risk MDS and CMML patients.

Представлены результаты лечения 8 больных миелодиспластическим синдромом (МДС) и 2 пациентов с хроническим миеломоноцитарным лейкозом (ХММоЛ) Дакогеном в курсовой дозе 100 мг/м2. Гематологический ответ по модифицированным критериям IWG констатирован у 70% больных, включая полную ремиссию у 2 пациентов, костно-мозговую – у 1 и стабилизацию болезни – у 4. У 1 больной с вторичным МДС и множественными хромосомными аберрациями после 2 курсов терапии получен полный цитогенетический ответ. Осложнения, послужившие причиной удлинения интервала между курсами, имели место у 3 пациентов. Полученные данные свидетельствуют об эффективности применения Дакогена при лечении больных МДС и ХММоЛ высокого риска.

myelodisplastic syndromechronic myelomonocytic leukemiaDacogenмиелодиспластический синдромхронический миеломоноцитарный лейкозДакоген1. Абдулкадыров К.М. Гематология. Новейший справочник по гематологии. М.: Эксмо; СПб.: Сова, 2005. 2. List A., Vardiman J., Issa J.-P., De Wite T.Абдулкадыров К.М. Гематология. Новейший справочник по гематологии. М.: Эксмо; СПб.: Сова, 2005. 2. List A., Vardiman J., Issa J.-P., De Wite T.Myelodysplastic syndromes. Hematology (Am Soc Hematol Educ Program) 2004:297–317.3. Грицаев С.В., Мартынкевич И.С., Абдулкадыров К.М. и др. Прогностический потенциал морфологических и цитогенетических показателей у больных миелодиспластическим синдромом. Тер арх 2005;(7):22–7.Грицаев С.В., Мартынкевич И.С., Абдулкадыров К.М. и др. Прогностический потенциал морфологических и цитогенетических показателей у больных миелодиспластическим синдромом. Тер арх 2005;(7):22–7.4. Greenberg P., Cox C., LeBeau M.M. et al. International scoring system for evaluation prognosis in myelodysplastic syndromes. Blood 1997;89(6):2079–88.Greenberg P., Cox C., LeBeau M.M. et al. International scoring system for evaluation prognosis in myelodysplastic syndromes. Blood 1997;89(6):2079–88.5. Kantarjian H., O’Brien S., Ravandi F. et al. Development and validation of a new prognostic model for myelodysplastic syndrome that accounts for events not considered by the International Prognostic Scoring System. Blood 2008;112(11):Abstr. 635.Kantarjian H., O’Brien S., Ravandi F. et al. Development and validation of a new prognostic model for myelodysplastic syndrome that accounts for events not considered by the International Prognostic Scoring System. Blood 2008;112(11):Abstr. 635.6. Rollison D., Howlader N., Smith M. et al. Epidemiology of myelodysplastic syndromees and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood 2008;112(1):45–52.Rollison D., Howlader N., Smith M. et al. Epidemiology of myelodysplastic syndromees and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood 2008;112(1):45–52.7. Deeg H. Optimization of transplant regimens for patients with myelodysplastic syndrome. Hematology (Am Soc Hematol Educ Program) 2005:167–73.Deeg H. Optimization of transplant regimens for patients with myelodysplastic syndrome. Hematology (Am Soc Hematol Educ Program) 2005:167–73.8. Martino R., Iacobelli S., Brand R. et al. Retrospective comparison of reducedintensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006;108(3):836–46.Martino R., Iacobelli S., Brand R. et al. Retrospective comparison of reducedintensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006;108(3):836–46.9. Garcia-Manero G. Modifying the epigenome as a therapeutic strategy in myelodysplasia. Hematology (Am Soc Hematol Educ Program) 2007:405–11.Garcia-Manero G. Modifying the epigenome as a therapeutic strategy in myelodysplasia. Hematology (Am Soc Hematol Educ Program) 2007:405–11.10. Giagounidis A., Fenaux P., Mufti G. et al. Practical recommendation on the use of lenalidomide in the management of myelodysplastic syndromes. Ann Hematol 2008;87(5):345–52.Giagounidis A., Fenaux P., Mufti G. et al. Practical recommendation on the use of lenalidomide in the management of myelodysplastic syndromes. Ann Hematol 2008;87(5):345–52.11. Kantarjian H., Oki Y., Issa J.-P. et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007;109(1):52–7.Kantarjian H., Oki Y., Issa J.-P. et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007;109(1):52–7.12. Kantarjian H., Garcia-Manero G., O’Brien S. et al. Survival and efficacy of decitabine in myelodysplastic syndromes, analysis of the 5-day IV dosing regimen. Blood 2007;110(11):Abstr. 115.Kantarjian H., Garcia-Manero G., O’Brien S. et al. Survival and efficacy of decitabine in myelodysplastic syndromes, analysis of the 5-day IV dosing regimen. Blood 2007;110(11):Abstr. 115.13. Kantarjian H., Issa J.-P., Rosenfeld C. et al. Decitabine improves patients outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006;106(8):1794–803.Kantarjian H., Issa J.-P., Rosenfeld C. et al. Decitabine improves patients outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006;106(8):1794–803.14. Musto P., Maurillo L., Spagnoli A. et al. 5-Azacytidine in 82 low/intermediate1 IPSS risk myelodysplastic syndromes: results from the Italian patient named program. Blood 2008;112(11):Abstr. 2680.Musto P., Maurillo L., Spagnoli A. et al. 5-Azacytidine in 82 low/intermediate1 IPSS risk myelodysplastic syndromes: results from the Italian patient named program. Blood 2008;112(11):Abstr. 2680.15. Nachtkamp K., Strupp C., Kuendgen A. et al. Clinical outcome of 40 patients with higher-risk myelodysplastic syndromes (MDS) after treatment with hypomethylating agents: a matched-pairs analysis. Blood 2008;112(11):Abstr. 2687.Nachtkamp K., Strupp C., Kuendgen A. et al. Clinical outcome of 40 patients with higher-risk myelodysplastic syndromes (MDS) after treatment with hypomethylating agents: a matched-pairs analysis. Blood 2008;112(11):Abstr. 2687.16. Wijermans P., L?bbert M., Verhoef G. et al. Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 2000;18(5):956–62.Wijermans P., L?bbert M., Verhoef G. et al. Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 2000;18(5):956–62.17. Vardiman J.W., Harris N.L., Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100(7):2292–302.Vardiman J.W., Harris N.L., Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100(7):2292–302.18. Garcia-Manero G., Shan J., Faderl S. et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 2008;22(3):538–43.Garcia-Manero G., Shan J., Faderl S. et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 2008;22(3):538–43.19. Kantarjian H., O'Brien S., Ravandi F. et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008;113(6):1351–61.Kantarjian H., O'Brien S., Ravandi F. et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008;113(6):1351–61.20. Sorror M., Maris M., Storb R. et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005;106(8):2912–9.Sorror M., Maris M., Storb R. et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005;106(8):2912–9.21. Cheson B., Greenberg P., Bennet J. et al. Clinical application and proposal for modification of the International Working Group response criteria in myelodysplasia. Blood 2006;108(2):419–25.Cheson B., Greenberg P., Bennet J. et al. Clinical application and proposal for modification of the International Working Group response criteria in myelodysplasia. Blood 2006;108(2):419–25.22. Jain N., Mattiuzzi G., Cortes J. et al. Benefit of anti-infectious prophylaxis in patients with acute myeloid leukemia or high-risk myelodysplastic syndrome receiving frontline ≪targeted therapy≫. Blood 2007;110(11):Abstr. 2858.Jain N., Mattiuzzi G., Cortes J. et al. Benefit of anti-infectious prophylaxis in patients with acute myeloid leukemia or high-risk myelodysplastic syndrome receiving frontline ≪targeted therapy≫. Blood 2007;110(11):Abstr. 2858.23. Sanz G.F. Which myelodysplastic syndromes patients are candidates for aggressive chemotherapy? Leuk Res 2007;31(Suppl 1):19.Sanz G.F. Which myelodysplastic syndromes patients are candidates for aggressive chemotherapy? Leuk Res 2007;31(Suppl 1):19.24. Estey E., Thall P., Cortes J. et al. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + aracbased regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blastas in transformation, or refractory anemia with excess blasts. Blood 2001;98(13):3575–83.Estey E., Thall P., Cortes J. et al. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + aracbased regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blastas in transformation, or refractory anemia with excess blasts. Blood 2001;98(13):3575–83.25. Fenaux P., Mufti G., Santini V. et al. Azacitidine treatment prolongs overall survival in higher-risk MDS patients compared with conventional care regimens: results of the AZA-001 phase III study. Blood 2007;110(11):Abstr. 817.Fenaux P., Mufti G., Santini V. et al. Azacitidine treatment prolongs overall survival in higher-risk MDS patients compared with conventional care regimens: results of the AZA-001 phase III study. Blood 2007;110(11):Abstr. 817.26. Zwierzina H., Suciu S., Loeffler-Ragg J. et al. Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group. Leukemia 2005;19(11):1929–33.Zwierzina H., Suciu S., Loeffler-Ragg J. et al. Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group. Leukemia 2005;19(11):1929–33.27. Kantarjian H., O’Brien S., Huang X. et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome. Comparision with historical experience. Cancer 2007;109(6):1133–7.Kantarjian H., O’Brien S., Huang X. et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome. Comparision with historical experience. Cancer 2007;109(6):1133–7.28. L?bbert M., Wijermans P., Kunzmann R. et al. Cytogenetic responses in highrisk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine. Br J Haematol 2001;114(2):349–57.L?bbert M., Wijermans P., Kunzmann R. et al. Cytogenetic responses in highrisk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine. Br J Haematol 2001;114(2):349–57.29. Kantarjian H., O’Brien S., Shan J. et al. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer 2007;109(2):265–73.Kantarjian H., O’Brien S., Shan J. et al. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer 2007;109(2):265–73.30. Silva L., Lima M., Kantarjian H. et al. Outcome of allogeneic stem cell transplantation after hypomethylating therapy with 2'-deoxy-5-azacytidine for patients with myelodysplastic syndrome. Blood 2007;110(11):Abstr. 1468.Silva L., Lima M., Kantarjian H. et al. Outcome of allogeneic stem cell transplantation after hypomethylating therapy with 2'-deoxy-5-azacytidine for patients with myelodysplastic syndrome. Blood 2007;110(11):Abstr. 1468.31. Kr?ger N. Epigenetic modulation and other options to improve outcome of stem cell transplantation in MDS. Hematology (Am Soc Hematol Educ Program) 2008:60–7.Kr?ger N. Epigenetic modulation and other options to improve outcome of stem cell transplantation in MDS. Hematology (Am Soc Hematol Educ Program) 2008:60–7.32. Estey E., Issa J.-P., Garcia-Manero G. et al. Use of post-treatment clinical data to predict response to decitabine. Blood 2007;110(11):Abstr. 1448.Estey E., Issa J.-P., Garcia-Manero G. et al. Use of post-treatment clinical data to predict response to decitabine. Blood 2007;110(11):Abstr. 1448.33. Issa J.-P., Castoro R., RavandiKashani F. et al. Randomized phase II study of combined epigenetic therapy: decitabine vs. decitabine and valproic acid in MDS and AML. Blood 2008;112(11):Abstr. 228.Issa J.-P., Castoro R., RavandiKashani F. et al. Randomized phase II study of combined epigenetic therapy: decitabine vs. decitabine and valproic acid in MDS and AML. Blood 2008;112(11):Abstr. 228.34. Kirschbaum M., Gojo I., Goldberg S. et al. Phase I study of vorinostat in combination with decitabine in patients with relapsed or newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. Blood 2008;112(11):Abstr. 3651.Kirschbaum M., Gojo I., Goldberg S. et al. Phase I study of vorinostat in combination with decitabine in patients with relapsed or newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. Blood 2008;112(11):Abstr. 3651.35. Voso M., Santini V., Finelli C. et al. 5-Azacytidine, valproic acid and all-trans retinoic acid in int-2/high risk myelodysplastic syndromes: results of the GIMEMA MDS0205 multicenter trial. Blood 2008;112(11):Abstr. 3648.Voso M., Santini V., Finelli C. et al. 5-Azacytidine, valproic acid and all-trans retinoic acid in int-2/high risk myelodysplastic syndromes: results of the GIMEMA MDS0205 multicenter trial. Blood 2008;112(11):Abstr. 3648.36. Sekeres M., Elson P., Kalaycio M. et al. Time from diagnosis to treatment initiation predict survival in younger, but not older, acute myeloid leukemia patients. Blood 2009;113(1):28–36.Sekeres M., Elson P., Kalaycio M. et al. Time from diagnosis to treatment initiation predict survival in younger, but not older, acute myeloid leukemia patients. Blood 2009;113(1):28–36.37. Steensma D., Baer M., Slack J. et al. Preliminary results of a phase II study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndrome. Blood 2007;110(11):Abstr. 1450.Steensma D., Baer M., Slack J. et al. Preliminary results of a phase II study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndrome. Blood 2007;110(11):Abstr. 1450.